Cancer Therapeutics Market Size, Products, Pipeline and Forecast, 2026–2035

Cancer Therapeutics Market Size and Forecast 2035

The global Cancer Therapeutics Market size was valued at US$189.34 billion in 2025 and is projected to reach US$620.32 billion by 2035, growing at a CAGR of 12.6% during 2026–2035.

The cancer therapeutics market comprises pharmaceutical and biological products used to treat solid tumors and hematologic malignancies. It includes cytotoxic chemotherapy, targeted small molecules, monoclonal antibodies, immune-checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies, hormonal therapies, cell therapies, radiopharmaceutical therapeutics, cancer vaccines and oncolytic-virus treatments.

The market is being reshaped by biomarker-guided prescribing, earlier use of advanced therapies, expansion into adjuvant and neoadjuvant settings, longer treatment duration and rapid development of antibody-drug conjugates, cell therapies, bispecific antibodies and radiopharmaceuticals.

Cancer incidence provides the underlying patient base but does not directly determine pharmaceutical revenue. In 2022, approximately 20 million new cancer cases and 9.7 million cancer deaths occurred worldwide. The annual number of new cases is projected to exceed 35 million by 2050. Actual commercial demand depends on diagnosis, cancer stage, biomarker status, treatment-line eligibility, access, product penetration, treatment duration, and net price.

This report measures manufacturer-level pharmaceutical and biological therapy revenue. It excludes external-beam radiotherapy, surgery, diagnostic testing, hospital treatment fees, screening services, and medical-device revenue unless analyzed separately.

Cancer Therapeutics Market Scope

Cancer Therapeutics Market Key Takeaways

• The market is projected to create approximately US$430.98 billion in additional annual revenue opportunities between 2025 and 2035.
• Immunotherapy, targeted therapies and antibody-drug conjugates are capturing a growing share of oncology revenue as treatment shifts from broad cytotoxic regimens toward biomarker- and immune-directed strategies.
• Chemotherapy remains commercially important, particularly in combination regimens, hematologic malignancies, resource-constrained markets and tumor settings without validated targeted options.
• North America remains the largest market because of high oncology-drug spending, rapid adoption of newly approved products, broad clinical-trial participation and premium pricing.
• Asia-Pacific is expected to grow fastest as China, Japan, South Korea, India and other markets expand diagnosis, reimbursement, domestic biotechnology development and access to advanced therapies.
• Keytruda remains one of the most commercially influential oncology franchises. Merck reported continued growth in 2025 from earlier-stage and metastatic indications, while the subcutaneous Keytruda Qlex formulation began contributing sales after its 2025 launch.
• Antibody-drug conjugates are expanding into earlier treatment lines. In December 2025, the FDA approved Enhertu with pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer.
• Patent expiries, biosimilar launches and generic competition will redistribute revenue from mature oncology products toward new formulations, combinations and next-generation modalities.

Cancer Therapeutics Market Definition and Exclusions

The cancer therapeutics market includes prescription pharmaceutical and biological products used to treat malignant solid tumors and blood cancers.

Included categories comprise:

• Branded oncology medicines
• Generic cytotoxic and targeted drugs
• Oncology biosimilars
• Immune-checkpoint inhibitors
• Monoclonal and bispecific antibodies
• Antibody-drug conjugates
• Autologous and allogeneic cell therapies
• Hormonal therapies
• Radiopharmaceutical therapeutics
• Cancer vaccines
• Oncolytic viruses
• Supportive oncology medicines where separately defined

Patient and Product-Based Market Model

The market forecast is built around treated-patient opportunity rather than cancer incidence alone.

For each indication:

Diagnosed patients × disease stage × biomarker eligibility × treatment-line eligibility × treated share × product penetration × treatment duration × net price = market revenue

A complete patient funnel includes:

1. Incident cancer population
2. Diagnosed population
3. Stage-specific population
4. Biomarker-tested patients
5. Biomarker-positive patients
6. Treatment-line-eligible patients
7. Reimbursed and accessible patients
8. Treated patients
9. Product share
10. Net annual revenue per patient

Example: Non-Small Cell Lung Cancer

A commercial model should distinguish:

• Resectable versus unresectable disease
• Localized versus metastatic disease
• Squamous versus non-squamous histology
• PD-L1 expression
• EGFR mutations
• ALK rearrangements
• ROS1 alterations
• BRAF mutations
• MET exon 14 skipping
• RET fusions
• NTRK fusions
• KRAS G12C
• HER2 alterations
• First-line versus later-line treatment

This structure prevents the entire lung-cancer population from being assigned to one therapeutic category.

Cancer Therapeutics Market Dynamics

Precision Oncology Expands Addressable Submarkets

Genomic and protein biomarkers are increasingly used to identify patients most likely to benefit from specific therapies.

Important commercial biomarkers include:

• HER2
• EGFR
• ALK
• ROS1
• RET
• NTRK
• BRAF
• KRAS
• MET
• BRCA and homologous-recombination deficiency
• PD-L1
• MSI-H and mismatch-repair deficiency
• BCMA
• CD19
• PSMA
• CLDN18.2
• Folate receptor alpha

Biomarker-defined markets may initially be smaller than broad chemotherapy populations but can support higher response rates, premium pricing and stronger product differentiation.

Earlier Treatment-Line Expansion Drives Revenue

Many advanced oncology medicines initially launch in heavily pretreated patients and later expand into first-line, adjuvant or neoadjuvant use.

Earlier-line approvals can increase:

• Eligible patient numbers
• Treatment duration
• Product penetration
• Clinical familiarity
• Combination use
• Revenue per patient

Merck attributed Keytruda’s 2025 growth partly to uptake in earlier-stage breast, lung, renal, cervical and head and neck cancers.

Antibody-Drug Conjugates Gain Commercial Importance

ADCs combine a target-specific antibody with a cytotoxic payload.

Commercial performance depends on:

• Target expression
• Linker stability
• Payload potency
• Bystander effect
• Resistance mechanisms
• Safety
• Manufacturing scalability
• Ability to move into earlier treatment lines

Enhertu, Datroway and other ADC platforms are increasing competition across breast, lung, gastric and additional solid tumors. AstraZeneca’s 2025 pipeline included multiple late-stage ADC programs directed at HER2, TROP2, CLDN18.2, FRα, EGFR/cMET and B7-H4 targets.

High Treatment Costs Limit Access

Advanced oncology regimens may combine:

• A branded biologic
• A targeted agent or ADC
• Chemotherapy
• Biomarker testing
• Infusion or procedure costs
• Supportive care

Payers increasingly evaluate total-regimen cost rather than the price of one medicine. Access can be restricted through prior authorization, biomarker requirements, treatment-center qualification and line-of-therapy rules.

Patent Expiries Reshape Revenue

Loss of exclusivity creates opportunities for generics and biosimilars while exposing originator companies to revenue erosion.

Portfolio strategies include:

• New indications
• Earlier treatment lines
• Subcutaneous formulations
• Fixed-dose combinations
• Next-generation molecules
• Companion products
• Geographic expansion
• Authorized generics
• Biosimilar defense

Therapy-Class Analysis

Immune-Checkpoint Inhibitors

Checkpoint inhibitors target immune-suppressive pathways such as PD-1, PD-L1 and CTLA-4.

Leading products include Keytruda, Opdivo, Imfinzi, Tecentriq and Yervoy.

The segment’s future depends on:

• Earlier-stage use
• Combination regimens
• Subcutaneous formulations
• Biomarker refinement
• New tumor indications
• Competition from bispecific antibodies
• Patent and biosimilar exposure

Keytruda Qlex was approved in September 2025 for subcutaneous administration across most adult solid-tumor indications covered by intravenous Keytruda. This reduces administration time and supports lifecycle management.

Targeted Small Molecules

Targeted small molecules include:

• Kinase inhibitors
• PARP inhibitors
• CDK4/6 inhibitors
• Proteasome inhibitors
• Epigenetic therapies
• Apoptosis-targeting drugs
• Protein degraders

Their commercial value depends on biomarker prevalence, resistance patterns, oral convenience and availability of next-generation inhibitors.

Products such as Tagrisso, Kisqali, Verzenio, Calquence, Lynparza and Xtandi remain important revenue drivers.

Monoclonal Antibodies

Monoclonal antibodies target tumor antigens, growth receptors, vascular pathways or immune mechanisms.

The segment includes:

• Naked antibodies
• Antiangiogenic antibodies
• Receptor-targeted antibodies
• Immune-engaging antibodies
• Bispecific and multispecific antibodies

Biosimilar competition has reduced revenue from mature products such as trastuzumab and bevacizumab while expanding access.

Antibody-Drug Conjugates

ADCs are among the fastest-expanding oncology modalities.

Key commercial targets include:

• HER2
• TROP2
• Nectin-4
• BCMA
• CD30
• FRα
• CLDN18.2
• B7-H4
• EGFR/cMET

The segment combines high clinical potential with significant manufacturing, linker, payload and safety complexity.

Bispecific Antibodies

Bispecific antibodies engage two targets, frequently including a tumor antigen and CD3 on T cells.

Important markets include:

• Multiple myeloma
• Lymphoma
• Leukemia
• Lung cancer
• Gastrointestinal cancers
• Other solid tumors

Commercial advantages include off-the-shelf availability compared with personalized cell therapy. Risks include cytokine-release syndrome, treatment-center burden and increasing competition.

Cell Therapies

Cell-therapy categories include:

• Autologous CAR-T
• Allogeneic CAR-T
• TCR-T
• Tumor-infiltrating lymphocytes
• NK-cell therapies

Revenue growth is supported by earlier treatment lines and new indications, but adoption remains constrained by manufacturing capacity, vein-to-vein time, treatment-center qualification and toxicity management.

Hormonal Therapies

Hormonal therapies remain central to breast and prostate cancer treatment.

Important classes include:

• Aromatase inhibitors
• Selective estrogen-receptor modulators
• Selective estrogen-receptor degraders
• CDK4/6 combinations
• Androgen-receptor inhibitors
• GnRH therapies

Oral SERDs and next-generation combinations are increasing competition in hormone-receptor-positive breast cancer.

Radiopharmaceutical Therapeutics

Radiopharmaceuticals deliver therapeutic radiation to molecular targets.

The segment includes:

• Beta-emitting therapies
• Alpha-emitting therapies
• PSMA-directed products
• Somatostatin-receptor therapies
• Targeted radionuclide conjugates

Commercial growth depends on isotope supply, radiopharmacy capacity, short-half-life logistics and treatment-center infrastructure.

Chemotherapy

Chemotherapy remains a major treatment component despite growth in targeted and immune therapies.

It is used:

• As monotherapy
• In multidrug combinations
• With checkpoint inhibitors
• In neoadjuvant and adjuvant settings
• As a conditioning or bridging treatment
• In cancers without actionable biomarkers

Generic competition limits revenue growth, but high patient volume preserves commercial importance.

Solid Tumors Versus Hematologic Malignancies

Solid Tumors

Major commercial categories include:

• Lung cancer
• Breast cancer
• Prostate cancer
• Colorectal cancer
• Melanoma
• Bladder cancer
• Renal-cell carcinoma
• Pancreatic cancer
• Liver cancer
• Gastric cancer
• Ovarian and endometrial cancers
• Head and neck cancer

Key growth drivers include checkpoint combinations, ADCs, biomarker testing, radiopharmaceuticals and earlier-stage treatment.

Hematologic Malignancies

Important categories include:

• Multiple myeloma
• Non-Hodgkin lymphoma
• Hodgkin lymphoma
• Chronic lymphocytic leukemia
• Acute myeloid leukemia
• Acute lymphoblastic leukemia
• Chronic myeloid leukemia
• Myelodysplastic syndromes

Growth is being driven by CAR-T therapies, bispecific antibodies, fixed-duration regimens, BCMA-directed products and next-generation oral targeted agents.

Cancer-Type Analysis

Lung Cancer

Lung cancer represents one of the largest and fastest-evolving pharmaceutical markets.

Revenue is distributed across:

• PD-1 and PD-L1 inhibitors
• EGFR inhibitors
• ALK and ROS1 inhibitors
• KRAS G12C inhibitors
• MET, RET and BRAF therapies
• ADCs
• Chemotherapy
• Antiangiogenic therapy

Treatment sequencing depends strongly on histology, stage and genomic testing.

Breast Cancer

Breast cancer generates substantial revenue across:

• HER2-targeted antibodies and ADCs
• CDK4/6 inhibitors
• Hormonal therapies
• PARP inhibitors
• Chemotherapy
• Checkpoint inhibitors

The December 2025 FDA approval of Enhertu plus pertuzumab in first-line metastatic HER2-positive breast cancer further strengthens the role of ADCs in earlier treatment.

Prostate Cancer

The prostate-cancer market includes:

• Androgen-receptor inhibitors
• Chemotherapy
• PARP inhibitors
• PSMA radiopharmaceuticals
• Hormonal therapies
• Emerging radioconjugates

Growth depends on earlier use, biomarker selection and sequencing of hormonal, targeted and radiopharmaceutical treatments.

Multiple Myeloma

Multiple myeloma is being transformed by:

• Anti-CD38 antibodies
• Proteasome inhibitors
• Immunomodulatory drugs
• BCMA CAR-T therapies
• BCMA bispecific antibodies
• Next-generation T-cell engagers

The market is highly competitive, and treatment sequencing is increasingly complex.

Product-Level Commercial Intelligence

Important oncology franchises include:

• Keytruda
• Opdivo
• Darzalex
• Tagrisso
• Enhertu
• Imfinzi
• Kisqali
• Verzenio
• Ibrance
• Lynparza
• Xtandi
• Erleada
• Pomalyst
• Jakafi
• Imbruvica
• Calquence
• Tecentriq
• Perjeta
• CAR-T products
• Radiopharmaceutical products

For every major product, the report evaluates:

• Company
• Active ingredient
• Modality
• Indication
• Treatment line
• Biomarker requirement
• Route
• 2025 revenue
• 2035 forecast
• Label-expansion opportunities
• Patent expiry
• Biosimilar or generic risk
• Main competitors

Merck reported full-year 2025 company sales of US$65.0 billion, with oncology-particularly Keytruda and Welireg-remaining a major source of growth.

Treatment-Line and Sequencing Analysis

Cancer therapeutics are segmented into:

• Neoadjuvant treatment
• Adjuvant treatment
• First-line metastatic treatment
• Maintenance treatment
• Second-line treatment
• Third and later lines
• Relapsed or refractory disease
• Salvage treatment
• Palliative treatment

A treatment-sequencing model includes:

Diagnosis → staging → biomarker testing → first-line therapy → response assessment → resistance testing → second-line therapy → later-line treatment

The same medicine may have different eligible populations, treatment duration and competitive positioning at each stage.

Route-of-Administration Analysis

Intravenous

Intravenous administration dominates biologics, ADCs and many chemotherapy regimens.

Commercial considerations include infusion capacity, administration time, buy-and-bill reimbursement and treatment-center access.

Oral

Oral targeted therapies and hormonal drugs support home treatment and specialty-pharmacy distribution.

Advantages include convenience, while adherence, drug interactions and patient cost sharing remain concerns.

Subcutaneous

Subcutaneous formulations can shorten chair time, improve patient convenience and protect product revenue before patent expiry.

Keytruda Qlex demonstrates the strategic importance of alternative checkpoint-inhibitor delivery.

Cellular Infusion and Radiopharmaceutical Administration

Cell therapies require qualified centers and specialized logistics. Radiopharmaceuticals depend on licensed administration sites, isotope supply and time-sensitive distribution.

Pipeline and Probability-Adjusted Forecasting

Pipeline products are classified as:

• Submitted or under regulatory review
• Phase III
• Phase II
• Phase I
• Preclinical
• Discontinued
• Partnered
• Rights returned

Each asset is evaluated using:

Eligible patients × expected penetration × annual net price × treatment duration × probability of approval × expected launch timing = probability-adjusted revenue

The pipeline database includes:

• Asset
• Company
• Modality
• Target
• Indication
• Treatment line
• Clinical phase
• Next catalyst
• Expected launch
• Probability of approval
• Peak-sales range

FDA approved 46 novel drugs across all therapeutic categories in 2025 and continued to issue numerous oncology indication and label-expansion decisions, illustrating the pace of market renewal.

2025–2026 Oncology Developments

September 2025 - Keytruda Qlex Approval

The FDA approved subcutaneous Keytruda Qlex for most adult solid-tumor indications covered by intravenous pembrolizumab. The formulation supports shorter administration and Merck’s lifecycle strategy.

November 2025 - Perioperative Bladder-Cancer Expansion

The FDA approved pembrolizumab or Keytruda Qlex with enfortumab vedotin as neoadjuvant treatment followed by adjuvant therapy after cystectomy in eligible muscle-invasive bladder cancer patients. The decision expands advanced therapy into curative-intent treatment.

December 2025 - First-Line Enhertu Combination

The FDA approved Enhertu with pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer. The approval increases ADC competition in a major first-line revenue segment.

2026 - Continued Accelerated-Approval Oversight

FDA continues to track accelerated oncology approvals with outstanding confirmatory-trial requirements. Products failing to verify clinical benefit may face restricted indications or withdrawal, creating material forecast risk.

Patent, Generic and Biosimilar Risk

For every major oncology franchise, the report assesses:

• Composition-of-matter expiry
• Method-of-use patents
• Formulation patents
• Biologic exclusivity
• Pediatric exclusivity
• Litigation
• Generic or biosimilar status
• Expected erosion
• Lifecycle strategy

Revenue at risk should be modeled as:

Current product revenue × exposed share × expected price erosion × expected switching rate

Key strategies include new indications, subcutaneous delivery, combination products and next-generation replacements.

Pricing and Reimbursement

Cancer-drug pricing differs substantially by country and treatment setting.

The report evaluates:

• US wholesale acquisition cost
• Estimated manufacturer net price
• European negotiated prices
• Japan reimbursement
• China national reimbursement inclusion
• Treatment-course cost
• Weight-based versus fixed dosing
• Combination-regimen cost
• Companion-testing cost
• Prior authorization
• Health-technology assessment
• Outcomes-based agreements
• Patient cost sharing

Approval does not automatically result in commercial access. Country forecasts distinguish regulatory approval, reimbursement, formulary adoption and actual treatment penetration.

Distribution Channels and Treatment Settings

Oncology-Specific Distribution Channels

• Hospital and oncology-center pharmacies
• Specialty pharmacies
• Physician-administered buy-and-bill
• Government and national-health procurement
• Retail pharmacies for oral oncology medicines
• Mail-order specialty distribution
• Cell-therapy centers
• Radiopharmacy networks
• Named-patient programs

Treatment Settings

• Academic medical centers
• Comprehensive cancer centers
• Community oncology practices
• Hospitals
• Ambulatory infusion centers
• Cell-therapy centers
• Radiopharmaceutical centers
• Home settings for eligible oral and subcutaneous treatments

Online pharmacy is relevant primarily to selected oral therapies and should not be treated as a universal channel for infused biologics, cell therapies or radiopharmaceuticals.

Manufacturing and Supply-Chain Analysis

Small Molecules

Key requirements include:

• High-potency API production
• Oral solid-dose manufacturing
• Global API sourcing
• Controlled handling
• Generic scalability

Monoclonal Antibodies and ADCs

Important bottlenecks include:

• Biologics capacity
• Linker and payload supply
• Conjugation
• Sterile fill-finish
• Analytical testing
• Cold chain

Cell Therapies

The supply chain includes:

• Apheresis
• Viral vectors
• Chain of identity
• Manufacturing slots
• Cryogenic logistics
• Treatment-center scheduling
• Vein-to-vein time

Radiopharmaceuticals

Critical factors include:

• Isotope availability
• Short half-life
• Radiopharmacy capacity
• Time-sensitive logistics
• Licensed treatment centers

Cancer Therapeutics Market Regional Analysis

North America Cancer Therapeutics Market

North America remains the largest cancer-therapeutics market.

The United States leads through premium pricing, rapid uptake of novel products, extensive biomarker testing, strong clinical-trial participation and broad availability of specialist oncology centers.

Market growth is being supported by ADCs, checkpoint inhibitors, cell therapies, radiopharmaceuticals and earlier-line approvals.

Europe Cancer Therapeutics Market

Europe is a major pharmaceutical market but access varies because of country-specific health-technology assessments and reimbursement negotiations.

Germany, France, Italy, Spain and the United Kingdom are key markets. Commercial uptake can lag regulatory approval where payers impose price or population restrictions.

Asia-Pacific Cancer Therapeutics Market

Asia-Pacific is expected to grow fastest.

Japan supports rapid adoption of innovative oncology medicines through an established reimbursement system. China is expanding domestic drug development and negotiated access, while South Korea and Australia have advanced treatment infrastructure.

India and Southeast Asia offer large patient populations but remain constrained by affordability, diagnosis and unequal access.

Cancer Therapeutics Market Competitive Landscape

Global Oncology Leaders

• Merck & Co.
• Bristol Myers Squibb
• Roche
• AstraZeneca
• Johnson & Johnson
• Novartis
• Pfizer
• AbbVie
• Eli Lilly
• Amgen
• Gilead Sciences
• Takeda
• Sanofi
• Bayer
• Astellas
• Daiichi Sankyo

Antibody-Drug Conjugate Leaders

• Daiichi Sankyo
• AstraZeneca
• Pfizer
• Gilead Sciences
• Roche
• AbbVie
• Merck & Co.

Cell-Therapy Leaders

• Gilead/Kite
• Bristol Myers Squibb
• Novartis
• Johnson & Johnson/Legend Biotech
• Autolus
• Allogene Therapeutics
• Caribou Biosciences

Radiopharmaceutical Participants

• Novartis
• Bayer
• Eli Lilly
• AstraZeneca
• Bristol Myers Squibb
• Specialist radiopharmaceutical developers

Companies compete through product revenue, clinical differentiation, biomarker reach, treatment-line expansion, pipeline strength, patents, pricing, manufacturing and geographic access.

Cancer Therapeutics Market Recent Developments

• June 2026 – Gilead expands first-line treatment options for triple-negative breast cancer
  The U.S. FDA approved sacituzumab govitecan (Trodelvy) as a first-line treatment for certain patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC), both as monotherapy and in combination with pembrolizumab for PD-L1-positive tumors. The approval strengthens the role of antibody-drug conjugates and immunotherapy combinations in cancer therapeutics.
• June 2026 – AstraZeneca advances targeted therapy for PTEN-deficient prostate cancer
  The FDA approved capivasertib (Truqap) in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. The development highlights the growing importance of biomarker-guided treatment strategies in oncology.
• June 2026 – Merck expands adjuvant cancer immunotherapy applications
  The FDA approved belzutifan (Welireg) in combination with pembrolizumab for the adjuvant treatment of adults with clear-cell renal cell carcinoma at intermediate-high or high risk of recurrence following surgery. The approval expands combination approaches integrating targeted therapy and immune checkpoint inhibition.
• June 2026 – Orca Bio advances cell-based immunotherapy for hematologic malignancies
  The FDA approved Orca Bio’s Tregzi, an allogeneic regulatory T-cell-based immunotherapy used with matched-donor hematopoietic stem cell transplantation in adults with hematologic malignancies. The approval represents continued progress in cell-based therapeutic approaches designed to improve transplant outcomes.
• May 2026 – Pfizer and Innovent expand global oncology drug development collaboration
  Pfizer and Innovent Biologics entered a strategic collaboration covering the research and development of 12 early-stage and de novo cancer medicines. The agreement includes antibody-drug conjugates with novel payloads and multispecific antibodies, highlighting continued industry investment in next-generation oncology therapeutics.
• May 2026 – Daiichi Sankyo expands antibody-drug conjugate treatment in triple-negative breast cancer
  The FDA approved datopotamab deruxtecan (Datroway) for adults with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval further demonstrates the expanding role of ADC technologies in targeted cancer treatment.
• May 2026 – Daiichi Sankyo expands HER2-targeted therapy into early-stage breast cancer
  The FDA approved trastuzumab deruxtecan (Enhertu) for two HER2-positive early-stage breast cancer indications, including neoadjuvant and adjuvant settings. The development broadens the use of HER2-directed ADC therapy beyond advanced disease.
• May 2026 – Biomarker-guided bladder cancer treatment gains momentum
  The FDA approved atezolizumab as an adjuvant treatment for certain patients with muscle-invasive bladder cancer who have circulating tumor DNA molecular residual disease following cystectomy. The decision highlights the increasing integration of molecular residual disease testing into treatment selection.
• May 2026 – Partner Therapeutics advances targeted therapy for rare cholangiocarcinoma
  The FDA approved zenocutuzumab (Bizengri) for advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion after prior systemic therapy. The development reinforces the shift toward precision oncology for genetically defined rare cancers.
• May 2026 – Arvinas advances targeted protein degradation in breast cancer
  The FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression on endocrine therapy. The approval highlights targeted protein degradation as an emerging therapeutic modality in oncology.
• March 2026 – Bristol Myers Squibb expands immunotherapy-based treatment for Hodgkin lymphoma
  The FDA approved nivolumab in combination with chemotherapy for previously untreated Stage III or IV classical Hodgkin lymphoma in adults and pediatric patients aged 12 years and older. The approval strengthens the role of checkpoint inhibition in frontline hematologic cancer treatment.
• March 2026 – Corcept advances therapy for platinum-resistant ovarian cancer
  The FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior systemic treatment regimens. The development adds another targeted combination option for difficult-to-treat gynecologic cancers.
• March 2026 – Janssen expands bispecific antibody therapy for multiple myeloma
  The FDA approved teclistamab in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma who had received at least one prior line of therapy. The decision reflects continued expansion of immune-engaging bispecific antibody approaches in hematologic malignancies.
• February 2026 – Pfizer expands precision treatment for BRAF-mutated colorectal cancer
  The FDA granted traditional approval to encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for adults with metastatic colorectal cancer carrying a BRAF V600E mutation. The development reinforces the market's shift toward molecularly selected oncology therapies.

Target Audience

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.